Additionally, for those with HF and LVEF of 40% or lower, the recommendation is to initiate therapy with SGLT2 inhibitors to reduce the risk of cardiovascular death and HF hospitalization and to improve QOL, regardless of whether the patient has diabetes (COR1).7 This evidence concerns the gene SLC5A2 and hydrops fetalis.